VOTRIENT 400MG TABLETS

Votrient 400mg Tablets contain pazopanib, a targeted anticancer medicine classified as a tyrosine kinase inhibitor (TKI). It is primarily prescribed for advanced renal cell carcinoma (kidney cancer) and certain soft tissue sarcomas in patients who have previously undergone chemotherapy. Votrient works by blocking proteins responsible for tumor growth and blood vessel formation, effectively slowing cancer progression.

This oral anticancer tablet must be taken strictly under oncologist supervision. Votrient 400 mg Tablets are often included in treatment protocols for patients with advanced cancers where standard chemotherapy may not be sufficient. Its targeted action helps minimize damage to healthy cells while maximizing the control of tumor growth.

Votrient 400 mg Tablets meet international quality and safety requirements for prescription oncology medicines. Suitable for hospital pharmacies, specialty oncology centers, and export supply, Votrient provides a reliable and trusted option for the management of advanced renal cell carcinoma and soft tissue sarcomas.

Product Features

• Targeted therapy tyrosine kinase inhibitor
• Used in kidney cancer and soft tissue sarcoma
• Inhibits tumor growth and angiogenesis
• Available in 200 mg and 400 mg strengths
• Oral tablet for convenient administration
• Prescription-only oncology medication

How It Helps

• Blocks tyrosine kinase proteins that drive cancer cell growth
• Inhibits angiogenesis to reduce blood supply to tumors
• Slows progression of kidney cancer and soft tissue sarcoma
• Provides targeted oral therapy under oncologist supervision